Introduction {#S0001}
============

Age-related macular degeneration (AMD) is the leading cause of blindness in patients over the age of 50 in developed countries.[@CIT0001]--[@CIT0007] The neovascular form of the disease (nAMD) is characterized by the abnormal growth of choroidal blood vessels beneath the macula that disrupts the anatomy and function of the neurosensory retina and causes severe and irreversible loss of vision.[@CIT0008]--[@CIT0010]

Ranibizumab (Lucentis^®^, Novartis, Basel, Switzerland and Genentech Inc., South San Francisco, CA, USA), a recombinant, humanized monoclonal antibody fragment that neutralizes all active forms of vascular endothelial growth factor A (VEGF-A), has been approved as intravitreal therapy for several retinal diseases, including nAMD (approved in 2006 in the US and in 2007 in Europe). While the efficacy and safety profile of ranibizumab use in nAMD is well established based on clinical trial evidence,[@CIT0009]--[@CIT0012] most evaluations of the longer-term (≥2 years) effectiveness and safety of ranibizumab in routine clinical practice have been limited-sample studies in one or a few countries.[@CIT0013]--[@CIT0019] In addition, treatment patterns of ranibizumab have not been extensively investigated in a real-world setting.

In order to provide an answer to these remaining questions, the LUMINOUS^TM^ study, a 5-year, global, multicenter, observational, open-label study that evaluated real-world ranibizumab use and associated outcomes in diverse populations, settings, and clinical practices for any approved indication included in the local product label, was conducted. Being the largest prospective observational trial in the medical retina field, this study recruited 30,138 patients from 488 sites in 42 countries.[@CIT0020]

We have previously reported on the 2-year[@CIT0013] and 6-year[@CIT0014] outcomes of treatment with ranibizumab for nAMD as observed in routine clinical practice in Belgium. Here, we assessed treatment patterns and associated outcomes in patients with nAMD of the Belgian (BE) cohort from the global LUMINOUS study, thus adding to the evidence base of real-world effectiveness and safety of ranibizumab use in Belgium.

Materials and Methods {#S0002}
=====================

Design, Sample and Setting {#S0002-S2001}
--------------------------

This analysis includes the Belgian nAMD subsample of the global, prospective, multicenter, observational, non-interventional, open-label, single-arm LUMINOUS study (NCT01318941). This 5-year study (March 2011-April 2016) recruited 30,138 consenting adults patients (≥18 years), enrolled by the local investigators at the participating outpatient clinics. Patients were previously treated with, currently treated with, or initiating treatment with ranibizumab for all approved indications per the local product label.[@CIT0020]

The global sample included 22,717 patients with nAMD. The LUMINOUS methodology has been detailed elsewhere.[@CIT0020] We summarize below key elements relevant to the LUMINOUS-BE analysis.

Being an observational study, all data were recorded as available from routine clinical practice on a clinical visit schedule determined by the treating physician. Patients not seen at least once per year were discontinued from the study. The overall duration of the study was 5 years, with a minimum of 1-year follow-up period per patient.

The primary eye with nAMD was the unit of observation and analyses were stratified by prior treatment status. Excluded were patients receiving systemic or ocular anti-VEGF therapy other than ranibizumab in the 90 or 30 days prior to enrollment, respectively, or participating in other investigational studies.

Variables and Measurement {#S0002-S2002}
-------------------------

Baseline data included socio-demographics, (non-)ocular medical history, prior (non-)ocular treatments, best-corrected visual acuity (VA), central retinal thickness (CRT), and start date and dose of ranibizumab therapy. The lesion characteristics were identified by the investigator and captured at start of study. Follow-up data included the administration date of ranibizumab, concomitant (non-)ocular treatments, (serious) adverse events (SAE/AE), reasons for discontinuation, VA, and CRT. The number of ranibizumab 0.5 mg injections was calculated per completed year of follow-up. Safety evaluations comprised the monitoring and assessment of occurrence, relationship, and severity of (non-)ocular AEs.

Effectiveness parameters used for long-term evaluation were: 1) change in best-corrected VA since baseline, expressed in (approximate) Early Treatment Diabetic Retinopathy Study (ETDRS) letters, and 2) change in CRT since baseline, expressed in µm. VA change was also categorized as gains of ≥15, 10--14, or 5--9 letters and VA status as the proportion of eyes with VA of ≥73 letters.

Statistical Analysis {#S0002-S2003}
--------------------

Patient demographics, medical history, ocular disease history, prior treatments, and other baseline characteristics were presented using standard descriptive statistics under consideration of applicable levels of measurement.

We applied linear mixed regression analysis, employing random intercepts to separate out within-center from between-center and within-patient from between-patient variability. Evaluation of changes over time among the prior treatment subgroups was achieved by entering an interaction of subgroup and time variables and specifying contrasts for specific hypotheses testing. The level of statistical significance was set at 0.05. All statistical analyses were performed using SAS^®^ v.9.4 (SAS Institute Inc., Cary, NC, USA).

Compliance {#S0002-S2004}
----------

LUMINOUS was designed, implemented, and reported in accordance with the Guidelines for Good Pharmacoepidemiology Practices issued by the International Society for Pharmacoepidemiology, with any applicable national guidelines, and with the ethical principles laid down in the Declaration of Helsinki. Approval was obtained from an Ethics Committee or Institutional Review Board at each participating center and all patients or their legal proxy gave written informed consent.

Results {#S0003}
=======

Sample Composition & Baseline Ocular Characteristics {#S0003-S2001}
----------------------------------------------------

Thirteen Belgian centers enrolled 229 patients with nAMD, with a mean age of 79.5±7.7 years ([Table 1](#T0001){ref-type="table"}). The majority of patients (67.7%) were female, and all patients were Caucasian.Table 1Patient Demographic and Clinical Characteristics at Study Entry, Study Discontinuation (N=229)ParametersValueAge: median, mean±SD (n)80.0, 79.5±7.7 (223)Gender: Male: n (%)74 (32.3)Comorbidities^a^: n (%) Hypertension119 (52.0) Hyper-cholesterolemia/-lipidemia107 (46.7) History of coronary artery disease28 (12.2) Diabetes19 (8.3) Obesity18 (7.9) Myocardial infarction14 (6.1) Stroke13 (5.7) Other thromboembolic event15 (6.6)Secondary eyes treated: n (%)53 (23.1)Ocular history^a^: n (%) Pigment epithelium detachment86 (37.6) Lesion type: Predominantly classic46 (20.1) Lesion size (\> 1 DA)151 (65.9) Choroidal neovascularization216 (94.3) Retinal angiomatous proliferation20 (8.7)Prior treatments: n (%) None (treatment-naïve)40 (17.5) Prior treatment (including ranibizumab)189 (82.5) Other prior treatments (not including ranibizumab)0 (0.0)Time (months) since diagnosis: median, mean±SD (n) All patients15.0, 28.3±37.1 (229) Treatment-naïve eyes0.0, 6.9±22.4 (40) Prior ranibizumab21.0, 32.8±38.0 (189)Ophthalmological parameters: median, mean±SD (n) Visual acuity (ETDRS letters)  All patients65.0, 62.9±14.0 (223)  Treatment-naïve60.0, 59.6±15.8 (37)  Prior ranibizumab65.0, 63.5±13.6 (186) Central retinal thickness (µm)  All patients275.0, 290.3±92.0 (223)  Treatment-naïve324.0, 341.2±92.0 (38)  Prior ranibizumab266.0, 279.8±88.7 (185)Study discontinuation: n (%)114 (49.8) Lost to follow-up43 (37.7)^b^ Switch to other anti-VEGF agent28 (24.6)^b^ Death18 (15.8)^b^ Subject withdrawal8 (7.0)^b^ Unsatisfactory therapeutic event5 (4.4)^b^ Protocol deviation4 (3.5)^b^ Adverse event4 (3.5)^b^ Study drug no longer needed2 (1.8)^b^ Administrative problems2 (1.8)^b^[^1][^2]

Mean follow-up time was 30.5±17.0 months, with half the patients discontinuing the study early (n=114; 49.8%) at an average of 13.6±13.4 months. Sample sizes at 1, 2, 3 and 4 years were 186 (81.2%), 139 (60.7%), 100 (43.7%) and 48 (21.0%), respectively. Primary reasons for premature study stop were loss to follow up (37.7%) or switch to another anti-VEGF agent (24.6%) ([Table 1](#T0001){ref-type="table"}). The most frequent non-ocular comorbidities were hypertension (n=119, 52.0%) and hypercholesterolemia/hyperlipidemia (n=107, 46.7%). With regard to the lesion characteristics, as captured at start of study by the investigators, about 20% (n=46) of patients had a lesion of the predominantly classic type and 86 (37.6%) patients had a pigment epithelium detachment. In total, 40 (17.5%) patients were treatment-naïve and the remaining 189 (82.5%) had been previously treated with ranibizumab (prior-ranibizumab).

At baseline, the mean VA was higher in patients treated previously with ranibizumab (63.5±13.6 letters) compared with treatment-naïve patients (59.6±15.8 letters). The mean baseline CRT, on the other hand, was lower in patients treated previously with ranibizumab (279.8±88.7 µm) compared with treatment-naïve patients (341.2±92.0 µm).

Treatment Patterns {#S0003-S2002}
------------------

The mean number of yearly visits was 7.9±2.8 for treatment-naïve and 7.5±2.9 for prior-ranibizumab patients ([Table 2](#T0002){ref-type="table"}).Table 2Number of Visits and Number of Ranibizumab Injections (N=229)Number of VisitsNumber of Injections**All patients**n^a^Median, mean±SDMedian, mean±SDYearly visits/injections (all years)4557.0, 7.6±2.94.0, 3.7±2.7 Year 11848.0, 7.9±2.64.0, 4.4±2.7 Year 21337.0, 7.1±2.43.0, 3.5±2.7 Year 3977.0, 7.4±3.13.0, 2.8±2.4 Year 4418.0, 8.7±4.14.0, 3.2±2.8**Treatment-naïve**n^a^Median, mean±SDMedian, mean±SDYearly visits/injections (all years)758.0, 7.9±2.84.0, 4.2±2.9 Year 1358.0, 8.4±3.15.0, 5.3±3.0 Year 2217.0, 7.3±2.13.0, 3.8±2.5 Year 3147.5, 8.0±3.02.5, 2.8±2.2 Year 457.0, 7.4±3.01.0, 2.4±2.5**Prior ranibizumab**n^a^Median, mean±SDMedian, mean±SDYearly visits/injections (all years)3807.0, 7.5±2.94.0, 3.6±2.7 Year 11497.0, 7.7±2.54.0, 4.2±2.6 Year 21127.0, 7.1±2.53.0, 3.4±2.8 Year 3837.0, 7.3±3.13.0, 2.8±2.5 Year 4368.0, 8.8±4.24.0, 3.3±2.8[^3][^4]

Regarding the mean number of yearly injections, treatment-naïve eyes received 4.2±2.9 yearly injections and eyes previously treated with ranibizumab 3.6±2.7, with an injection frequency declining over time irrespective of prior treatment status (p\<0.0001). With the decline in frequency, an increase in time intervals between injections was observed ([[Table S1](https://www.dovepress.com/get_supplementary_file.php?f=242547.docx)]{.ul}).

Besides unstable VA, the most common reason for re-treatment was optical coherence tomography abnormalities at 62.3% and 63.9% of re-treatments in treatment-naïve and prior-ranibizumab cohorts, respectively ([[Table S2](https://www.dovepress.com/get_supplementary_file.php?f=242547.docx)]{.ul}).

Visual Acuity {#S0003-S2003}
-------------

Quarterly changes in letters read compared to baseline for treatment-naïve and prior-ranibizumab eyes are presented in [Figure 1](#F0001){ref-type="fig"} (see [[Table S3](https://www.dovepress.com/get_supplementary_file.php?f=242547.docx)]{.ul} for point estimates). For treatment-naïve eyes, regression analysis confirmed first-year increases with annual VA change estimates of β=3.9 (95% CI: 1.5, 6.3; p=0.002; [[Table S4](https://www.dovepress.com/get_supplementary_file.php?f=242547.docx)]{.ul}). After the first year, VA decreased slightly by −1.8 letters per year (β= −1.8; 95% CI: −2.9, −0.7; p=0.001). For prior-ranibizumab-treated eyes, changes over 1 year were statistically non-significant at 0.03±11.7 (β=−0.1; 95% CI: −1.2, 1.1; p=0.90). After 1 year, VA declined slightly in prior-ranibizumab eyes (β= −1.7; 95% CI: −2.2, −1.2; p\<0.0001).Figure 1Mean VA change (in ETDRS letters ± standard errors) from baseline per quarter.**Notes:** Pre-treatment status category of the eye: Treatment-naïve= ![](OPTH_A_242547_O_ILF0001.jpg){#ILF0001}; Prior ranibizumab = ![](OPTH_A_242547_O_ILF0002.jpg){#ILF0002}. Baseline n (month 0)=number of patients; all other n=number of measurements within the quarter (multiple assessments per patient possible).**Abbreviations:** ETDRS, Early Treatment Diabetic Retinopathy Study; VA, visual acuity.

Across years 1 through 4, between 33.3% and 53.3% of treatment-naïve eyes and between 30.4% and 36.3% of prior-ranibizumab eyes attained ≥73 letters read ([[Table S5](https://www.dovepress.com/get_supplementary_file.php?f=242547.docx)]{.ul}). Gains of at least 5 letters (ie, sum of eyes with ≥5, ≥10, and ≥15 letters gained) ranged from 47.6% to 66.7% for treatment-naïve and from 32.9% to 39.5% for prior-ranibizumab over all 4 years.

Central Retinal Thickness {#S0003-S2004}
-------------------------

Quarterly changes in CRT compared to baseline for treatment-naïve and prior-ranibizumab eyes are depicted in [Figure 2](#F0002){ref-type="fig"} (see [[Table S3](https://www.dovepress.com/get_supplementary_file.php?f=242547.docx)]{.ul} for point estimates). Regression analysis ([[Table S4](https://www.dovepress.com/get_supplementary_file.php?f=242547.docx)]{.ul}) showed that the CRT of treatment-naïve eyes decreased over time at a rate of −14.0 µm per year from baseline (95% CI: −18.6, −9.4; p\<0.0001), whereas prior-ranibizumab eyes remained stable (β=−0.8, 95% CI: −2.7, 1.1, p=0.43).Figure 2Mean CRT change (in µm ± standard errors) from baseline per quarter.**Notes:** Pre-treatment status category of the eye: Treatment-naïve= **![](OPTH_A_242547_O_ILF0003.jpg){#ILF0003}**; Prior ranibizumab = **![](OPTH_A_242547_O_ILF0004.jpg){#ILF0004}**. Baseline n (month 0)=number of patients; all other n=number of measurements within the quarter (multiple assessments per patient possible).**Abbreviations:** CRT, central retinal thickness; µm, micrometer.

Safety {#S0003-S2005}
------

Ocular AEs were reported in 64 (27.9%) patients (treatment-naïve: 22 \[55.0%\], prior-ranibizumab: 42 \[22.2%\]) ([[Table S6](https://www.dovepress.com/get_supplementary_file.php?f=242547.docx)]{.ul}). Non-ocular AEs were reported in 100 (43.7%) patients (treatment-naïve: 17 \[42.5%\], prior-ranibizumab: 83 \[43.9%\]) ([[Table S6](https://www.dovepress.com/get_supplementary_file.php?f=242547.docx)]{.ul}). Ocular adverse events suspected to be treatment-related (ranibizumab and/or ocular injection) were reported for 14 (6.1%) patients (treatment-naïve: 5 \[12.5%\], prior-ranibizumab: 9 \[4.8%\]), the most common of which were conjunctival haemorrhage, endophthalmitis, and eye pain ([[Table S7](https://www.dovepress.com/get_supplementary_file.php?f=242547.docx)]{.ul}). Five (2.6%) prior-ranibizumab patients experienced seven non-ocular AEs suspected to be related to ranibizumab and/or ocular injection ([[Table S7](https://www.dovepress.com/get_supplementary_file.php?f=242547.docx)]{.ul}). Eleven (4.8%) patients had ocular SAEs, leading to discontinuation of ranibizumab for 3 patients (1.3%); however, only two (0.9%) were suspected to be treatment related. Sixty (26.2%) patients experienced non-ocular SAEs, six (2.6%) of which were suspected to be treatment related but did not result in treatment discontinuation. An additional four patients had ocular and two had non-ocular AEs (all non-serious) leading to discontinuation. There were 18 deaths (7.9%) during the study period, none of which were suspected to be treatment-related.

Discussion {#S0004}
==========

This analysis of the Belgian patients with nAMD in the real-world LUMINOUS study consisted of 229 treatment-naïve or prior-ranibizumab-treated patients with an average follow-up of 2.5 years.

The outcomes for the treatment-naïve eyes were largely consistent with data from previous longer-term real-world studies of ranibizumab,[@CIT0013]--[@CIT0019] including two Belgian studies reporting on 2-year and 6-year outcomes.[@CIT0013],[@CIT0014] Although variability was detected in the VA and CRT values, overall, a generally well-preserved mean VA was observed, with an initial gain that was gradually lost over time (−1.8 letters/year). Anatomically, a sustained decrease in mean CRT was recorded to study end. This discrepancy in long-term visual and anatomic results is consistent with prior findings.[@CIT0014],[@CIT0018],[@CIT0021] Similarly, the prior-ranibizumab eyes showed a slight decline (−1.7 letters/year) in VA from year 1 onwards, but stable CRT throughout the study period. Reasonably, though pre-ranibizumab VA and CRT parameters were not available for the previously ranibizumab-treated eyes, (many of) these eyes had probably already achieved a therapeutic benefit by the start of the LUMINOUS study and entered the study with stable disease.

Of note, the VA and CRT outcomes observed in this study were associated with a rather low mean number of yearly injections and a steadily declining injection frequency over time. Several studies have reported a relationship between anti-VEGF treatment frequency and VA outcomes.[@CIT0013],[@CIT0018],[@CIT0019],[@CIT0022]--[@CIT0025] For instance, in SEVEN-UP,[@CIT0025] a multicenter, non-interventional cohort study of 65 patients originally treated with ranibizumab in the ANCHOR and MARINA trials and the HORIZON extension, showed that better visual outcomes were obtained among intensively treated patients, suggesting an association with injection frequency. One retrospective study[@CIT0018] evaluating an as-needed ranibizumab regimen over 5 years also found a positive association between number of injections and improvements in VA, suggesting the benefit of regular treatment beyond the initial phase. The retrospective AURA study[@CIT0019] demonstrated that more frequent visits (ie, monitoring) and injections (ie, re-treatments) were associated with maintenance of VA gains.

The PRN dosing schedule with treatment guidance by VA and/or optical coherence tomography was the regimen of choice in Belgium during the LUMINOUS study. In individualized, reactive, as-needed anti-VEGF regimens, monitoring frequency and re-treatment criteria impact effectiveness.[@CIT0012],[@CIT0026]-[@CIT0028] Being a chronic, progressive disease, nAMD requires sustained monitoring and treatment for many years.[@CIT0015],[@CIT0016],[@CIT0025] However, (re-)treatment inertia may be responsible for irreversible VA deterioration;[@CIT0029] thus, PRN regimens should include monthly monitoring in order to treat any recurrence as soon as possible prior to lasting VA damage. A recent secondary analysis of the Comparison of Age-Related Macular Degeneration Treatment Trial, a randomized clinical trial, has shown that visit adherence contributes to visual acuity outcomes.[@CIT0030] In the current analysis, the mean number of yearly visits was 7.6±2.9, which is not as strict as the monthly monitoring in clinical trials and reflects the contingencies of real-life situations, such as practical feasibility and patients' willingness and ability to comply. Indeed, in the setting of routine clinical practice, where patients are not followed as intensively as in clinical trials nor treated in accordance with a study protocol, the undertreatment may be accompanied by multiple recurrences of pronounced exudation, potentially damaging photoreceptors and thus leading to vision loss.[@CIT0029],[@CIT0031] This may explain the functional deterioration noticed in this Belgian analysis despite morphologic response to therapy.

Since nAMD patients often require anti-VEGF treatment for many years, evaluation of the long-term ocular and non-ocular safety is necessary. Overall, the ocular and non-ocular AEs observed in the Belgian nAMD sample of the LUMINOUS study were consistent with the types of AEs observed in prior controlled studies and consistent with the well-established safety profile of ranibizumab. No new safety findings were identified.

Limitations of this LUMINOUS-BE analysis are similar to those of the parent global LUMINOUS study. First, due to convenience sampling, selection bias cannot be excluded. Furthermore, as this was a study on real-world ranibizumab practice patterns and outcomes, all patients were treated with ranibizumab and there was no comparison group of untreated patients or patients treated only with other therapies. Lastly, as described in other long-term real-world studies,[@CIT0016],[@CIT0032],[@CIT0033] the study discontinuation rate was significant in the current analysis with half of the patients stopping the study prematurely. Although the data reflect the long-term patient journey in real-life practice, the dropout rate in combination with the rather small sample size may affect the reliability of the effectiveness results, primarily beyond the first year. In analogy with the 2-year Belgian HELIOS study,[@CIT0013] lost-to-follow-up was the main cause for patient drop-out in the current analysis. Recently a study highlighted the significant visual acuity decline observed after a period of being lost to follow-up.[@CIT0034] Factors related to poor follow-up adherence have been identified in previous studies and include among others older age, greater distance to hospital, and lower baseline vision.[@CIT0016],[@CIT0032],[@CIT0035] Though loss of patients from regular follow-up in the long-term is inevitable, these findings highlight the importance of identifying patients at risk and exploring measures to improve proper therapy adherence in order to avoid the deleterious effects caused by a gap in care.

Notwithstanding these limitations and bearing in mind the natural evolution of the disease, the current Belgian sample of the LUMINOUS reconfirms the well-characterized benefit-risk profile of ranibizumab for treatment of nAMD in a real-world clinical setting and adds to the growing body of evidence of the long-term real-world effectiveness and safety of ranibizumab. The observed low injection frequency reflects a need for more rigorous treatment in real-world settings. As such, the real-world evidence from this study may help guide Belgian clinicians in optimizing the frequency of ranibizumab injections in the management of nAMD and counseling patients undergoing long-term anti-VEGF therapy in clinical practice.

Conclusions {#S0005}
===========

LUMINOUS-BE reports long-term real-world ranibizumab treatment patterns and clinical outcomes in nAMD patients that supports the well-characterized benefit-risk profile of ranibizumab. A PRN dosing schedule prevailed in Belgium at the time and a pattern of relative under-treatment was observed, consistent with other real-world studies utilizing this approach.

The authors thank all Belgian centers that participated in the LUMINOUS study for their data acquisition and/or research execution.
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[^1]: **Notes:** ^a^Categories not mutually exclusive; ^b^% of patients who discontinued the study (n=114).

[^2]: **Abbreviations:** DA, disc area; ETDRS, Early Treatment Diabetic Retinopathy Study; SD, standard deviation; VEGF, vascular endothelial growth factor; µm, micrometer.

[^3]: **Notes:** ^a^n=number of visits/treatments for eyes up to their last completed year.

[^4]: **Abbreviation:** SD, standard deviation.
